Biomea Fusion, Inc. Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities
Biomea Fusion, Inc. (BMEA) reported Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities of -$107.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities · last filed 2026-08-05
- Biomea Fusion, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-06-30 was $2.86M.
- Biomea Fusion, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-03-31 was -$2.96M, a 173.72% decline year-over-year.
- Biomea Fusion, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-12-31 was -$1.96M.
- Biomea Fusion, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-09-30 was $400.00K.
- Biomea Fusion, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2025 was -$255.00K.
- Biomea Fusion, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2024 was -$6.88M, a 464.85% decline from fiscal 2023.
- Biomea Fusion, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2023 was $1.89M, a 78.84% decline from fiscal 2022.
- Biomea Fusion, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2022 was $8.91M, a 322.46% increase from fiscal 2021.
| Period end | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 3 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 6 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 9 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.86M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$107.00K 10-Q · filed 2026-08-05 | -$2.07M derived: sum of 3 quarters · filed 2026-08-05 | -$1.67M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$2.96M 10-Q · filed 2026-05-11 | -$4.93M derived: sum of 2 quarters · filed 2026-05-11 | -$4.53M derived: sum of 3 quarters · filed 2026-05-11 | -$7.24M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$1.96M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | -$1.56M derived: sum of 2 quarters · filed 2026-03-24 | -$4.28M derived: sum of 3 quarters · filed 2026-08-05 | -$255.00K 10-K · filed 2026-03-24 |
| 2025-09-30 | $400.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$2.31M derived: sum of 2 quarters · filed 2026-08-05 | $1.71M 10-Q · filed 2025-11-04 | -$7.52M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$2.71M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $1.31M 10-Q · filed 2026-08-05 | -$7.92M derived: sum of 3 quarters · filed 2026-08-05 | -$8.08M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $4.02M 10-Q · filed 2026-05-11 | -$5.21M derived: sum of 2 quarters · filed 2026-05-11 | -$5.36M derived: sum of 3 quarters · filed 2026-05-11 | -$6.70M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | -$9.23M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | -$9.38M derived: sum of 2 quarters · filed 2026-03-24 | -$10.72M derived: sum of 3 quarters · filed 2026-03-24 | -$6.88M 10-K · filed 2026-03-24 |
| 2024-09-30 | -$153.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$1.49M derived: sum of 2 quarters · filed 2025-11-04 | $2.35M 10-Q · filed 2025-11-04 | $5.70M derived: sum of 4 quarters · filed 2026-03-24 |
| 2024-06-30 | -$1.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $2.50M 10-Q · filed 2025-08-05 | $5.86M derived: sum of 3 quarters · filed 2026-03-24 | $8.56M derived: sum of 4 quarters · filed 2026-03-24 |
| 2024-03-31 | $3.84M 10-Q · filed 2025-05-05 | $7.19M derived: sum of 2 quarters · filed 2026-03-24 | $9.89M derived: sum of 3 quarters · filed 2026-03-24 | $6.54M derived: sum of 4 quarters · filed 2026-03-24 |
| 2023-12-31 | $3.35M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | $6.06M derived: sum of 2 quarters · filed 2026-03-24 | $2.71M derived: sum of 3 quarters · filed 2026-03-24 | $1.89M 10-K · filed 2026-03-24 |
| 2023-09-30 | $2.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-29 | -$643.00K derived: sum of 2 quarters · filed 2024-10-29 | -$1.47M 10-Q · filed 2024-10-29 | -$201.00K derived: sum of 4 quarters · filed 2025-03-31 |
| 2023-06-30 | -$3.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-31 | -$4.17M 10-Q · filed 2024-07-31 | -$2.91M derived: sum of 3 quarters · filed 2025-03-31 | $1.13M derived: sum of 4 quarters · filed 2025-03-31 |
| 2023-03-31 | -$823.00K 10-Q · filed 2024-05-02 | $442.00K derived: sum of 2 quarters · filed 2025-03-31 | $4.47M derived: sum of 3 quarters · filed 2025-03-31 | $5.97M derived: sum of 4 quarters · filed 2025-03-31 |
| 2022-12-31 | $1.26M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $5.30M derived: sum of 2 quarters · filed 2025-03-31 | $6.80M derived: sum of 3 quarters · filed 2025-03-31 | $8.91M 10-K · filed 2025-03-31 |
| 2022-09-30 | $4.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-30 | $5.53M derived: sum of 2 quarters · filed 2023-10-30 | $7.65M 10-Q · filed 2023-10-30 | $6.55M derived: sum of 4 quarters · filed 2024-03-28 |
| 2022-06-30 | $1.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-07-31 | $3.62M 10-Q · filed 2023-07-31 | $2.52M derived: sum of 3 quarters · filed 2024-03-28 | $3.47M derived: sum of 4 quarters · filed 2024-03-28 |
| 2022-03-31 | $2.12M 10-Q · filed 2023-05-02 | $1.02M derived: sum of 2 quarters · filed 2024-03-28 | $1.97M derived: sum of 3 quarters · filed 2024-03-28 | $3.14M derived: sum of 4 quarters · filed 2024-03-28 |
| 2021-12-31 | -$1.09M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | -$149.00K derived: sum of 2 quarters · filed 2024-03-28 | $1.02M derived: sum of 3 quarters · filed 2024-03-28 | $2.11M 10-K · filed 2024-03-28 |
| 2021-09-30 | $946.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $2.11M derived: sum of 2 quarters · filed 2022-11-07 | $3.21M 10-Q · filed 2022-11-07 | $3.68M derived: sum of 4 quarters · filed 2023-03-28 |
| 2021-06-30 | $1.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-01 | $2.26M 10-Q · filed 2022-08-01 | $2.73M derived: sum of 3 quarters · filed 2023-03-28 | $2.85M derived: sum of 4 quarters · filed 2023-03-28 |
| 2021-03-31 | $1.09M 10-Q · filed 2022-05-16 | $1.57M derived: sum of 2 quarters · filed 2023-03-28 | $1.69M derived: sum of 3 quarters · filed 2023-03-28 | |
| 2020-12-31 | $476.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | $596.00K derived: sum of 2 quarters · filed 2023-03-28 | $588.00K 10-K · filed 2023-03-28 | |
| 2020-09-30 | $120.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $112.00K 10-Q · filed 2021-11-03 | ||
| 2020-06-30 | -$8.00K 10-Q · filed 2021-08-11 | |||
| 2019-12-31 | $10.00K 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B |